|
Hyperplastic polyp (HP)
|
24
|
21 (88%)
|
2 (8.3%)
|
1 (4.2%)
|
3 (13%)
|
|
Sessile serrated polyp/adenoma (SSA)
|
7
|
5 (71%)
|
2 (29%)
|
0
|
2 (29%)
|
|
Mixed polyp with SSA and adenoma (MP)
|
5
|
4 (80%)
|
1 (20%)
|
0
|
1 (20%)
|
|
Total HP, SSA and MP
|
36
|
30 (83%)
|
5 (14%)
|
1 (2.8%)
|
6 (17%)
|
|
Traditional serrated adenoma
|
27
|
8 (30%)
|
14 (52%)
|
5 (19%)
|
19 (70%)
|
|
Tubular adenoma (TA)
|
393
|
154 (39%)
|
132 (34%)
|
107 (27%)
|
239 (61%)
|
|
Tubulovillous adenoma (TVA)
|
109
|
49 (45%)
|
27 (25%)
|
33 (30%)
|
60 (55%)
|
|
Villous adenoma (VA)
|
13
|
5 (38%)
|
5 (38%)
|
3 (23%)
|
8 (62%)
|
|
Total non-serrated adenomas (TA, TVA, and VA)
|
515
|
208 (40%)
|
164 (32%)
|
143 (28%)
|
307 (60%)
|
|
Adenoma with intramucosal carcinoma
|
33
|
8 (24%)
|
11 (33%)
|
14 (42%)
|
25 (76%)
|
|
Adenocarcinoma with serration
|
96
|
13 (14%)
|
18 (19%)
|
65 (68%)
|
83 (86%)
|
|
Adenocarcinoma without serration
|
111
|
18 (16%)
|
23 (21%)
|
70 (63%)
|
93 (84%)
|
|
Total adenocarcinomas
|
207
|
31 (15%)
|
41 (20%)
|
135 (65%)
|
176 (85%)
|
